ImageneBio
IMA | NASDAQ
$3.20
-$0.27 (-7.78%)
At close: Nov 16, 2026, 4:00 PM ET
$3.20
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:10 PM ET
-7.78%
(1D)No price chart data available for 1D timeframe.
Rating
25.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #910/1021 (Top 89%)
Key Statistics
Market Data
Market Cap $54.79M
1D Range
3.13 3.36
52W Range
3.13 7.70
Valuation (TTM)
PE -1.03
PB 0.43
EV/EBITDA 1.60
Valuation (NTM)
Forward PE N/A
Forward PEG 0.03
Price Target $1.33
Cash Flow
FCF Yield -74.1%
SBC Adj. FCF Yield -80.5%
SBC Impact -8.6%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -67.8% |
-80.7%
Dil EPS 3Y | 5Y 51.9% |
18.5%
FCF 3Y | 5Y 21.3% |
15.3%
Returns
ROA -30.4%
ROE -32.9%
ROIC -36.4%
Financial Health
Net Cash
$126.6M
Current Ratio 16.17
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, ...
Sector Healthcare
Industry Biotechnology
Employees 18
IPO Date Feb 27, 1998
Website www.inmagenebio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Sell
Price Target
$1.33
Downside
-58.44%
Buy (0)
Hold (0)
Sell (1)
Add to Watchlist
Select watchlists to add or remove IMA